The Southern comfort food chain, still reeling from a failed rebrand and customer discontent, now requires traveling staff to eat primarily at its own locations—a move seen as an effort to bolster internal revenue.
Oracle's deepening role as TikTok's U.S. data guardian and its aggressive push into regulated AI sectors present a dual narrative of strategic growth and heightened operational scrutiny, following a service outage linked to its infrastructure.
As global travel surges past pre-pandemic records, the influx of visitors is straining infrastructure and reshaping communities worldwide. From European protests to quiet American suburbs, the quest for authentic experiences is colliding with local life, fueling a housing crisis and raising a critical question: can cities belong to both residents and tourists?
The Trump administration has escalated pressure on Cuba by declaring a national emergency and threatening punitive tariffs on countries supplying it with oil, while simultaneously finalizing a reciprocal trade agreement with Guatemala aimed at bolstering Western Hemisphere supply chains.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
Private equity giant Thoma Bravo is exploring a sale of Imprivata, a key player in healthcare digital identity software, in a deal that could value the company at up to $7 billion, sources tell Reuters.
RBC Capital reaffirms its Outperform rating on UnitedHealth Group, citing management's commitment to long-term earnings targets, even as a lower-than-expected Medicare Advantage rate proposal triggers a sharp sell-off in the health insurer's shares.
Newly released federal data confirms Texas led all states in job creation last year, setting new historic highs for total employment, workforce size, and nonfarm jobs in December, even as regional disparities persist.
While Wall Street analysts are overwhelmingly bullish on several stocks, their optimistic price targets often come with a caveat. We examine one company where the enthusiasm appears justified and two where underlying challenges suggest a more cautious approach.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
While small-cap stocks can offer overlooked opportunities, their high-risk nature demands careful scrutiny. We examine three companies where valuation and business concerns suggest caution may be warranted.
The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.
Secretary-General António Guterres warns the United Nations could exhaust its regular budget cash by July, citing chronic non-payment of dues by member states and a "Kafkaesque" financial cycle that threatens its core operations.
Under new CEO César Vargas, the family-owned group is breaking into five autonomous business units in a bid to boost agility and market responsiveness, as it eyes growth beyond its €900m turnover.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
